JP2020521490A5 - - Google Patents

Download PDF

Info

Publication number
JP2020521490A5
JP2020521490A5 JP2019566198A JP2019566198A JP2020521490A5 JP 2020521490 A5 JP2020521490 A5 JP 2020521490A5 JP 2019566198 A JP2019566198 A JP 2019566198A JP 2019566198 A JP2019566198 A JP 2019566198A JP 2020521490 A5 JP2020521490 A5 JP 2020521490A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
seq
sequence defined
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566198A
Other languages
English (en)
Japanese (ja)
Other versions
JP7460370B2 (ja
JP2020521490A (ja
Filing date
Publication date
Priority claimed from GBGB1708655.4A external-priority patent/GB201708655D0/en
Application filed filed Critical
Publication of JP2020521490A publication Critical patent/JP2020521490A/ja
Priority to JP2021141016A priority Critical patent/JP7560420B2/ja
Publication of JP2020521490A5 publication Critical patent/JP2020521490A5/ja
Priority to JP2022109106A priority patent/JP7406593B2/ja
Application granted granted Critical
Publication of JP7460370B2 publication Critical patent/JP7460370B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566198A 2017-05-31 2018-05-29 細胞培養方法 Active JP7460370B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021141016A JP7560420B2 (ja) 2017-05-31 2021-08-31 細胞培養方法
JP2022109106A JP7406593B2 (ja) 2017-05-31 2022-07-06 細胞培養方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1708655.4A GB201708655D0 (en) 2017-05-31 2017-05-31 Cell culture methods
GB1708655.4 2017-05-31
PCT/EP2018/064102 WO2018219968A1 (en) 2017-05-31 2018-05-29 Cell culture methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021141016A Division JP7560420B2 (ja) 2017-05-31 2021-08-31 細胞培養方法

Publications (3)

Publication Number Publication Date
JP2020521490A JP2020521490A (ja) 2020-07-27
JP2020521490A5 true JP2020521490A5 (https=) 2022-06-16
JP7460370B2 JP7460370B2 (ja) 2024-04-02

Family

ID=59270991

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019566198A Active JP7460370B2 (ja) 2017-05-31 2018-05-29 細胞培養方法
JP2021141016A Active JP7560420B2 (ja) 2017-05-31 2021-08-31 細胞培養方法
JP2022109106A Active JP7406593B2 (ja) 2017-05-31 2022-07-06 細胞培養方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021141016A Active JP7560420B2 (ja) 2017-05-31 2021-08-31 細胞培養方法
JP2022109106A Active JP7406593B2 (ja) 2017-05-31 2022-07-06 細胞培養方法

Country Status (21)

Country Link
US (3) US12077796B2 (https=)
EP (2) EP3630946B1 (https=)
JP (3) JP7460370B2 (https=)
KR (3) KR20200012972A (https=)
CN (2) CN119326882A (https=)
AU (2) AU2018276376C1 (https=)
BR (1) BR112019024390A2 (https=)
CA (1) CA3065661A1 (https=)
CL (1) CL2019003459A1 (https=)
CO (1) CO2019012871A2 (https=)
EA (1) EA201992828A1 (https=)
ES (1) ES2978394T3 (https=)
GB (1) GB201708655D0 (https=)
HR (1) HRP20240585T1 (https=)
HU (1) HUE066922T2 (https=)
IL (2) IL270880B2 (https=)
MX (1) MX2019014140A (https=)
MY (1) MY193535A (https=)
PL (1) PL3630946T3 (https=)
RU (2) RU2021128024A (https=)
WO (1) WO2018219968A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
JP2023554489A (ja) * 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
GB202105424D0 (en) * 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes
WO2025262319A1 (en) 2024-06-21 2025-12-26 Boehringer Ingelheim International Gmbh Modifying blue color formation in bioprocesses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
SI2078071T1 (sl) * 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
US8030027B2 (en) * 2008-04-29 2011-10-04 St. Jude Children's Research Hospital Method for enhancing recombinant antibody production
US8252557B2 (en) 2008-10-28 2012-08-28 Chugai Seiyaku Kabushiki Kaisha Peptide-containing culture medium for culturing animal cell
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
RU2563353C2 (ru) 2010-04-26 2015-09-20 Новартис Аг Улучшенная среда для культивирования клеток
PL2563906T3 (pl) 2010-04-26 2018-04-30 Novartis Ag Sposób hodowli komórek cho
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
JP2016513478A (ja) * 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
CN106715707A (zh) 2014-06-18 2017-05-24 免疫医疗公司 包含n‑乙酰半胱氨酸的细胞培养方法和培养基
WO2016108765A1 (en) 2014-12-29 2016-07-07 Wirojpaisi Wanlop Engine combustion system oxygen efficiency enhancing device with raised electrical voltage and improved installation method
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
KR102425040B1 (ko) 2016-04-28 2022-07-25 메르크 파텐트 게엠베하 단백질 내 트리술파이드 수준을 감소시키기 위한 방법
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
WO2018018613A1 (zh) * 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN106222129A (zh) 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods

Similar Documents

Publication Publication Date Title
JP2020521490A5 (https=)
IL276164B1 (en) Anti-tmprss2 antibodies and antigen-binding fragments
JP2022519068A5 (https=)
JP2022523442A5 (https=)
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
HRP20110187T1 (hr) Multispecifične deimunizirane tvari koje vežu cd3
CA3166139C (en) Engineered anti-il-2 antibodies
JP2021094022A5 (https=)
JP2017508463A (ja) 抗ｉｌ−１７抗体、その生産および使用のための方法
JP2022122865A5 (https=)
JP2021503938A5 (https=)
JP7560420B2 (ja) 細胞培養方法
JP2024544523A5 (https=)
JP2021185185A5 (https=)
EP4628095A1 (en) Fusion protein and granulated antigen comprising same
JP2023522417A5 (https=)
JP2024509701A5 (https=)
JP2025537544A5 (ja) 融合タンパク質及びそれを含む粒子状抗原
JP2024546759A5 (https=)
JP2023507280A5 (https=)
CN118852428A (zh) 抗EGFR抗体的生产方法、对于FcγRIIIa的亲和性提升方法及抗EGFR抗体
JP2025503707A5 (https=)
CN115551877A (zh) 组合物和方法
JP2023505219A5 (https=)
RU2024139604A (ru) Антитела к bcma